Bionomics Limited Files 8-K

TL;DR

BIONOMICS FILES 8-K: VOTES AND FINANCIALS REPORTED.

AI Summary

Bionomics Limited filed an 8-K on December 11, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing does not contain specific details on the votes or financial figures within the provided text.

Why It Matters

This filing indicates that Bionomics Limited has submitted matters for a vote and is providing financial statements, which are standard corporate disclosures.

Risk Assessment

Risk Level: low — This is a routine corporate filing without immediate material financial or operational news.

Key Players & Entities

• BIONOMICS LIMITED (company) — Registrant
• December 11, 2024 (date) — Date of earliest event reported
• 200 Greenhill Road Eastwood, SA Australia 5063 (address) — Principal executive offices

FAQ

Filing Documents

• ea0224532-8k_bionomics.htm (8-K) — 32KB
• ea022453201ex99-1_bionomics.htm (EX-99.1) — 14KB
• ex99-1_001.jpg (GRAPHIC) — 3KB
• 0001213900-24-108436.txt ( ) — 226KB
• bnox-20241211.xsd (EX-101.SCH) — 3KB
• bnox-20241211_lab.xml (EX-101.LAB) — 33KB
• bnox-20241211_pre.xml (EX-101.PRE) — 22KB
• ea0224532-8k_bionomics_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders As discussed in two Current Reports on Form 8-K that were filed with the Securities and Exchange Commission on October 2, 2024 and November 8, 2024, Bionomics Limited, an Australian corporation ("Bionomics"), and Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), have entered into a Scheme Implementation Agreement to re-domicile from Australia to the U.S. State of Delaware pursuant to a Scheme of Arrangement under Australian law. Upon completion of the Scheme of Arrangement, Bionomics would become a wholly-owned subsidiary of Neuphoria. At a special meeting held at 4:30 pm on December 11, 2024 New York time / 8:30 am on December 12, 2024 Sydney time, Bionomics shareholders approved, by the requisite majority, the Scheme of Arrangement. Voting Results In summary: 96% of the votes cast by Bionomics shareholders were in favor of the Scheme; and 87% of Bionomics shareholders present and voting (in person or by proxy, attorney or corporate representative) voted in favor of the Scheme. Next Steps Although Bionomics shareholder approval has been obtained, the Scheme remains subject to a number of customary conditions detailed in the Scheme Implementation Agreement, including: the Supreme Court of New South Wales approving the Scheme at a hearing currently scheduled to occur at 3:00pm Sydney time on December 16, 2024 ("Second Court Hearing"); the independent expert not withdrawing or adversely modifying its conclusion that the Scheme is in the best interest of Bionomics shareholders; and the satisfaction or waiver of any remaining conditions prior to the Second Court Hearing. of the Scheme is expected to occur on or about December 24, 2024.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 12, 2024, issued by Bionomics Limited. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIONOMICS LIMITED Date: December 12, 2024 By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR